Judy Tsai, MD
Hematology & Oncology · Akron, OHNPI 1376773010
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,116 of the $1,417 with a category attached, or 78.7%. It is spread thinly across 19 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $503 and has fallen 50.9% since, to $247 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 36 payments — averaging $39.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$219
- AstraZeneca$141
- Genentech USA, Inc.$138
- Jazz Pharmaceuticals Inc.$122
- Amgen$122
- Astellas Pharma US Inc$113
- plus $562 from 13 others
Across 2 payments — averaging $9546.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Myriad Genetic Laboratories, Inc.$19K
- Merck$500
What the payments were for
- Food & beverage$1,11679%
- Education$30121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $219 |
| AstraZeneca | 3 | $141 |
| Genentech USA, Inc. | 1 | $138 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Amgen | 1 | $122 |
| Astellas Pharma US Inc | 2 | $113 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $98 |
| Eisai Inc. | 4 | $90 |
| AbbVie | 1 | $83 |
| GSK | 3 | $67 |
| Novartis | 3 | $52 |
| Genmab U.S., Inc. | 2 | $44 |
| Legend Biotech USA Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Caris MPI, Inc. | 1 | $17 |
| Pfizer | 1 | $14 |
| Pharmaessentia USA Corporation | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,417 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 34 | $603,214 |
| Lenalidomide | 43 | $514,515 |
| IbrancePalbociclib | 26 | $402,712 |
| ImbruvicaIbrutinib | 23 | $377,015 |
| XtandiEnzalutamide | 25 | $356,079 |
| VerzenioAbemaciclib | 13 | $192,270 |
| CalquenceAcalabrutinib Maleate | 12 | $186,223 |
| TasignaNilotinib Hcl | 11 | $181,678 |
| ErleadaApalutamide | 12 | $89,619 |
| Abiraterone Acetate | 60 | $85,638 |
| EliquisApixaban | 61 | $59,129 |
| OrgovyxRelugolix | 19 | $47,708 |
| Anastrozole | 200 | $3,550 |
| Ondansetron Hcl | 77 | $2,560 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 70 | $1,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $14 | $461,84087 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $98 | $377,01523 claims |
| Astellas Pharma US IncXtandi | $113 | $356,07925 claims |
| Lilly USA, LLCVerzenio | $18 | $192,27013 claims |
| AstraZenecaCalquence | $141 | $186,22312 claims |
| NovartisTasigna | $52 | $181,67811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Akron
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.